Chief Operating Officer
Adrian P. Kells, PhD
Dr. Kells obtained his PhD at the University of Auckland, New Zealand, following postgraduate research investigating AAV vector delivery for Huntington's disease. He went on to join the Bankiewicz Laboratory at UCSF as a Postdoctoral Fellow and as a Postdoctoral Researcher, with an interest in translational neuroscience. At UCSF for 6 years, Dr. Kells was involved in a variety of IND-enabling research studies and also developed regulatory affairs skills in association with preclinical investigations targeting clinically-relevant approaches, including gene therapy for Parkinson’s disease. Dr. Kells transitioned to Voyager Therapeutics, Inc, shortly after it was founded, and over a 5-year tenure advanced from Senior Scientist to Director Clinical Science helping to advance their Parkinson’s disease gene therapy efforts until leaving to join BrainNeuBio. Dr. Kells has over 30 peer-reviewed publications and is co-inventor on a number of issued patents.